Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote

Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.

Why Is Horizon Therapeutics (HZNP) Up 7.5% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.

Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Beat Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 25.49% and 0.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HZNP or BMRN: Which Is the Better Value Stock Right Now?

HZNP vs. BMRN: Which Stock Is the Better Value Option?

Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus

Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.

Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus

Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.

Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review

Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.

Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 36.84% and 7.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to Decline

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.

Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

Horizon Pharma (HZNP) Q1 Earnings and Revenues Top Estimates

Horizon Pharma (HZNP) delivered earnings and revenue surprises of 200.00% and 18.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Axsome (AXSM) This Earnings Season?

On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

Guardant Health (GH) to Report Q1 Earnings: What's in Store?

At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

Proteostasis (PTI) to Post Q1 Earnings: What's in Store?

During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.

What's in the Cards for Nektar (NKTR) This Earnings Season?

The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.

What's in Cards for Cumberland (CPIX) This Earnings Season?

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

What's in the Cards for Perrigo (PRGO) This Earnings Season?

Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.